New partnership aims to advance vaccine against MERS coronavirus
“We had a head-start in our development of the Oxford/AstraZeneca COVID-19 vaccine, thanks to the many years already spent researching a vaccine for another coronavirus, MERS.
- “We had a head-start in our development of the Oxford/AstraZeneca COVID-19 vaccine, thanks to the many years already spent researching a vaccine for another coronavirus, MERS.
- “There is an active need for a MERS vaccine for at-risk populations and travellers in the Middle East.
- MERS is a severe respiratory infection caused by MERS-CoV, a coronavirus that was first identified in 2012 in Saudi Arabia.
- The vaccine will be made available to low- and middle-income countries at a price no higher than the cost of manufacturing plus 10 percent.